(1) The Board of
Medical Examiners and the Board of Pharmacy shall promulgate a standard
formulary of legend drugs and/or drug classes consistent with the
recommendations of the Joint Committee that may be utilized under an
Any Formulary that
includes prescription drugs and/or drug classes additional to the standard
Formulary shall be submitted to the Joint Committee for recommendation for
approval. When evaluating whether to recommend the approval or denial of the
addition of a drug or drug class to a Formulary, the Joint Committee shall
consider certain factors, including, but not limited to:
(a) The Collaborating Physician's and
Collaborating Pharmacist's education, training, experience, and
(b) The Collaborating
Physician's and Collaborating Pharmacist's disciplinary history and any
approved usages and recommendations;
(d) Whether the usage of the proposed drug(s)
or drug class(es) is within the current standard of care for treatment of the
disease or condition specified in the Protocol, including usages known as
"off-label," and whether the use is supported by evidence-based
(e) Whether the use of
the proposed drug(s) or drug class(es) creates an undue risk of harm to
(f) The routine scope
of practice and services provided by the Collaborating Physician and the
(3) After consideration of the factors listed
herein, the Joint Committee may recommend approval or denial of the addition of
a drug or drug class to a Formulary.
Ala. Admin. Code r.
Administrative Monthly Volume XXXIX, Issue No. 11, August 31,
2021, eff. 10/15/2021.
Author: Alabama Board of Medical
Code of Ala.
Act 2019-368 (Code of Ala. 1975, §